These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 7907129)
21. [Hypertension management in general practice in Iceland]. Jensdóttir JO; Sigurethsson EL; Thornorgeirsson G Laeknabladid; 2006 May; 92(5):375-80. PubMed ID: 16741320 [TBL] [Abstract][Full Text] [Related]
22. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs. Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973 [TBL] [Abstract][Full Text] [Related]
23. Primary prevention with beta-blockade in patients with hypertension: review of results and clinical implications. Wikstrand J J Cardiovasc Pharmacol; 1990; 16 Suppl 5():S64-75. PubMed ID: 11527139 [TBL] [Abstract][Full Text] [Related]
24. Beta-blockers and diuretics. The HAPPHY and MAPHY studies. Berglund G Clin Exp Hypertens A; 1989; 11(5-6):1137-48. PubMed ID: 2571434 [TBL] [Abstract][Full Text] [Related]
25. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Dahlöf B; Sever PS; Poulter NR; Wedel H; Beevers DG; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J; Lancet; 2005 Sep 10-16; 366(9489):895-906. PubMed ID: 16154016 [TBL] [Abstract][Full Text] [Related]
26. Predictors of cardiovascular morbidity in treated hypertension: results from the primary preventive trial in Göteborg, Sweden. Samuelsson O; Wilhelmsen L; Elmfeldt D; Pennert K; Wedel H; Wikstrand J; Berglund G J Hypertens; 1985 Apr; 3(2):167-76. PubMed ID: 4020124 [TBL] [Abstract][Full Text] [Related]
27. Continued importance of diuretics and beta-adrenergic blockers in the management of hypertension. Moser M; Setaro J Med Clin North Am; 2004 Jan; 88(1):167-87. PubMed ID: 14871058 [TBL] [Abstract][Full Text] [Related]
29. Thiazide diuretics and selective alpha blockers: comparison of use in antihypertensive therapy, including possible differences in coronary heart disease risk reduction. Grimm RH Am J Med; 1987 Jan; 82(1A):26-30. PubMed ID: 2879460 [TBL] [Abstract][Full Text] [Related]
30. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Vijan S; Hayward RA Ann Intern Med; 2003 Apr; 138(7):593-602. PubMed ID: 12667032 [TBL] [Abstract][Full Text] [Related]
31. Factors related to the development of diabetes during a 20-year follow-up. A prospective study in a homogeneous group of middle-aged men. Strandberg TE; Salomaa V Nutr Metab Cardiovasc Dis; 2000 Oct; 10(5):239-46. PubMed ID: 11213532 [TBL] [Abstract][Full Text] [Related]
32. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. Black HR; Elliott WJ; Grandits G; Grambsch P; Lucente T; White WB; Neaton JD; Grimm RH; Hansson L; Lacourciere Y; Muller J; Sleight P; Weber MA; Williams G; Wittes J; Zanchetti A; Anders RJ; JAMA; 2003 Apr 23-30; 289(16):2073-82. PubMed ID: 12709465 [TBL] [Abstract][Full Text] [Related]
33. Residual coronary risk in men aged 50-59 years treated for hypertension and hyperlipidaemia in the population: the PRIME study. Blacher J; Evans A; Arveiler D; Amouyel P; Ferrières J; Bingham A; Yarnell J; Haas B; Montaye M; Ruidavets JB; Ducimetière P; J Hypertens; 2004 Feb; 22(2):415-23. PubMed ID: 15076202 [TBL] [Abstract][Full Text] [Related]
35. Antihypertensive therapy and the concept of total cardiovascular protection. Mason DT; Chan MC; Lee G Am J Cardiol; 1987 Sep; 60(9):29E-32E. PubMed ID: 2889351 [TBL] [Abstract][Full Text] [Related]
36. Metabolic disturbances increasing the risk of coronary heart disease during diuretic-based antihypertensive therapy: lipid alterations and glucose intolerance. Ames RP Am Heart J; 1983 Nov; 106(5 Pt 2):1207-14. PubMed ID: 6637786 [TBL] [Abstract][Full Text] [Related]
38. Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. Wikstrand J; Warnold I; Olsson G; Tuomilehto J; Elmfeldt D; Berglund G JAMA; 1988 Apr; 259(13):1976-82. PubMed ID: 3346979 [TBL] [Abstract][Full Text] [Related]
39. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Fontbonne A; Eschwège E; Cambien F; Richard JL; Ducimetière P; Thibult N; Warnet JM; Claude JR; Rosselin GE Diabetologia; 1989 May; 32(5):300-4. PubMed ID: 2666216 [TBL] [Abstract][Full Text] [Related]
40. Drug treatment of the hypertensive diabetic. Kendall MJ; Lewis H; Griffith M; Barnett AH J Hum Hypertens; 1988 Mar; 1(4):249-58. PubMed ID: 2906093 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]